Treatment of chronic sinusitis with nasal polyps Review article

Article Sidebar

PDF (Język Polski)


Published: Nov 17, 2025
DOI: https://doi.org/10.24292/01.AP.214891225
Keywords:
CRSwNP, nasal polyps, intranasal pharmacotherapy, pulsed nebulisation

Main Article Content

Piotr Rapiejko
Klinika Otolaryngologii i Onkologii Laryngologicznej z Klinicznym Oddziałem Chirurgii Czaszkowo-Szczękowo- -Twarzowej, Wojskowy Instytut Medyczny – Państwowy Instytut Badawczy w Warszawie
http://orcid.org/0000-0003-3868-0294

Abstract

Chronic rhinosinusitis with nasal polyps is a heterogeneous condition characterised by a predominant type 2 inflammatory mechanism, leading to tissue remodelling and the formation of polyps. Despite the availability of numerous treatment options, a significant proportion of patients do not achieve satisfactory symptom control. This paper focuses on conservative treatment, with particular emphasis on intranasal pharmacotherapy, its limitations arising from anatomical conditions, and dosage optimisation. The role of appropriate drug dosing and the significance of limitations on aerosol penetration within the nasal cavities are highlighted.

Downloads

Download data is not yet available.

Article Details

How to Cite
Rapiejko, P. (2025). Treatment of chronic sinusitis with nasal polyps. Alergoprofil, 21(4), 20-26. https://doi.org/10.24292/01.AP.214891225
Issue
Vol 21 No 4 (2025)
Section
Article

Copyright: ? Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Fokkens WJ, Lund VJ, Hopkins C et al. European Position Paper on Rhinosinusitis and Nasal Polyps. Rhinology. 2020; 58(Suppl S29): 1-464. http://doi.org/10.4193/rhin20.600.
2. Jurkiewicz D, Kupczyk M, Brozek-Madry E et al. Biologicals in the treatment of chronic rhinosinusitis – position of the Polish Society of Otorhinolaryngologists – Head and Neck Surgeons and the Polish Society of Allergology experts. Otolaryngol Pol. 2023; 77(2): 1-11. http://doi.org/10.5604/01.3001.0053.5965.
3. Rot P, Rapiejko P, Jurkiewicz D. Intranasal steroid therapy – EPOS 2020. Otolaryngol Pol. 2020; 74(3): 41-9. http://doi.org/10.5604/01.3001.0014.2449.
4. Rapiejko P, Jurkiewicz D, Sosnowski TR. Zależność efektu działania donosowych glikokortykosteroidów od depozycji leku w jamach nosa. Alergoprofil. 2016; 12(1): 5-10.
5. Rapiejko P, Sosnowski TR, Sova J et al. Deposition of intranasal glucocorticoids – preliminary study. Otolaryngol Pol. 2015; 69(6): 30-8. http://doi.org/10.5604/00306657.1184545.
6. Zhang Y, Lou H, Wang Y et al. Comparison of Corticosteroids by Approaches to the Treatment of Chronic Rhinosinusitis With Nasal Polyps. Allergy Asthma Immunol Res. 2019; 11(4): 482-97. http://doi.org/10.4168/aair.2019.11.4.48.
7. Charakterystyka produktu leczniczego. Nebbud 0,5/ml .
8. www.parisinus.pl www.parisinus.pl.